Broker Forecast - Barclays Capital issues a broker note on AstraZeneca PLC

Writer, Stock Market Wire
Friday, September 13, 2019 - 10:10

Barclays Capital today reaffirms its overweight investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 8200p (from 8000p).

Broker Forecasts data provided by www.sharesmagazine.co.uk


Related content

AstraZeneca's breast cancer drug granted priority review in US

AstraZeneca said the US Food and Drug Administration had granted the priority review for its metastatic breast cancer drug.

The review date for the...

Thu, 17/10/2019 - 08:20


Broker Forecast - Jefferies International issues a broker note on AstraZeneca PLC

Jefferies International today reaffirms its hold investment rating on AstraZeneca PLC (LON:AZN) and raised its price target to 6700p (from 6550p).

Broker Forecasts data provided...

Tue, 15/10/2019 - 09:20


Dudley helps BP overcome deadly legacy

While he will probably be disappointed with BP’s share price performance during his nine-year tenure as the oil major’s CEO, Bob Dudley will be...

Fri, 04/10/2019 - 15:15


AstraZeneca's respiratory drug gets regulatory nod in US for self-administration

AstraZeneca said the US Food and Drug Administration had approved the self-administration of the company’s respiratory medication in a pre-filled pen.

The company said...

Fri, 04/10/2019 - 07:26


AstraZeneca sells rights to heart-burn medication to Cheplapharm for up to $266m

AstraZeneca said it had agreed to sell the global commercial rights for its heart-burn medication and associated brands to Cheplapharm for up to $266m.

Under...

Tue, 01/10/2019 - 08:00